Payment overview · 2025
General Payments
$57.14
3 reported records · 2 companies
Healthcare provider profile · identity verified
Robert D Multari, DO
Allopathic & Osteopathic Physicians|Internal Medicine · FARRELL, PA · NPI 1619950417
Verified facts
What the public records show
CMS Open Payments records show Robert D Multari, DO received $57.14 in general payments during 2025 across 3 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 60.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.45 | 60.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.69 | 39.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $57.14 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1145 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 779 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 661 | 34 |
| Gabapentin | Gabapentin | 389 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 358 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 357 | 85 |
| Morphine Sulfate | Morphine Sulfate | 346 | 13 |
| Methadone Hcl | Methadone Hcl | 310 | suppressed |
| Alprazolam | Alprazolam | 289 | 17 |
| Potassium Chloride | Potassium Chloride | 271 | 45 |
| Lisinopril | Lisinopril | 253 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 47 |
| Tramadol Hcl | Tramadol Hcl | 211 | 25 |
| Lorazepam | Lorazepam | 210 | 29 |
| Farxiga | Dapagliflozin Propanediol | 209 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 194 | 43 |
| Clonazepam | Clonazepam | 193 | suppressed |
| Furosemide | Furosemide | 180 | 43 |
| Metformin Hcl | Metformin Hcl | 177 | 39 |
| Methylprednisolone | Methylprednisolone | 173 | 83 |
| Eliquis | Apixaban | 161 | 28 |
| Glimepiride | Glimepiride | 160 | 30 |
| Azithromycin | Azithromycin | 155 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 147 | 13 |
| Celecoxib | Celecoxib | 138 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 136 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 33 |
| Omeprazole | Omeprazole | 127 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 123 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 108 | 28 |
| Allopurinol | Allopurinol | 104 | 23 |
| Trazodone Hcl | Trazodone Hcl | 103 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 66 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 18 |
| Montelukast Sodium | Montelukast Sodium | 86 | 13 |
| Topiramate | Topiramate | 82 | suppressed |
| Ibuprofen | Ibuprofen | 81 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 15 |
| Famotidine | Famotidine | 80 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 77 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 20 |
| Carvedilol | Carvedilol | 75 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 75 | suppressed |
| Diazepam | Diazepam | 74 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 72 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 16 |
| Chlorthalidone | Chlorthalidone | 63 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 18 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Cephalexin | Cephalexin | 56 | 37 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Digoxin | Digoxin | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 11 |
| Valacyclovir | Valacyclovir Hcl | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Prednisone | Prednisone | 47 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 15 |
| Glipizide | Glipizide | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Carisoprodol | Carisoprodol | 42 | suppressed |
| Losartan Potassium | Losartan Potassium | 42 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Meloxicam | Meloxicam | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 26 |
| Atenolol | Atenolol | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Etodolac | Etodolac | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Naproxen | Naproxen | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 11 |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57.14 · 3 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | PAXLOVID, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error